norstella-logo-white

News & events

Keep up with the latest news, insights and events from Norstella and its market-leading brands

News | Insights | Events

News

Press Releases | Dec. 04, 2023

MMIT wins Titan Health Award for healthcare innovation

December 4, 2023, Yardley, PA – MMIT, a Norstella company and the trusted go-to-market partner for overcoming barriers to patient access, is excited to announce that its Patient Access Analytics solution has won a Titan Health Award, which celebrates and recognizes extraordinary achievements in healthcare advertising and marketing. Read more
Press Releases | May. 16, 2023

Industry veteran Fred Hassan joins the board of Norstella

Norstella, a leader in helping patients gain access to life-saving therapies by navigating the complexities at each step of the drug development life cycle, is pleased to announce that Fred Hassan has joined its board of directors. Hassan brings a wealth of experience and expertise in healthcare, having served as CEO of several major pharmaceutical companies and as a board member of numerous healthcare organizations. He has held senior leadership roles at some of the world's most prominent organizations, including Schering-Plough, Pharmacia Corporation, and Bausch & Lomb. Read more
Press Releases | Apr. 04, 2023

TriNetX and Clinerion unite as TriNetX and Norstella announce strategic partnership

Cambridge, MA, April 4, 2023 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of novel therapies, and Norstella, the leading pharmaceuticals solutions provider, today announced a multi-faceted strategic partnership. As part of this exciting partnership, TriNetX will acquire Norstella’s Clinerion Ltd. subsidiary, expanding the growth of the world’s leading research network for real world data (RWD). Read more
Press Releases | Mar. 30, 2023

Citeline launches TrialScope intelligence, meeting the growing complexities of clinical trial disclosure

Clinical trial disclosure compliance is challenging, whether a sponsor is registering five trials or 500 trials. Compounding the complexity is the fact that no global standards exist for disclosure. With ever-changing global regulations, new requirements on the rise and the threat of monetary penalties, study sponsors are feeling the pressure to maintain compliance, minimize risk and safeguard their brand reputation. Read more
In the News | Mar. 07, 2023

How robust data technology is transforming the design and execution of viable clinical trials

While incorporating real-world data (RWD) and real-world evidence (RWE) across the drug development lifecycle is getting a lot of attention, the application of such insights gleaned from rigorous analysis to the design and execution of clinical trials has yet to be widely adopted, despite its potential to address some of these persistent challenges. Read more
In the News | Jan. 08, 2023

What do you view as the most disruptive or transformational technology or development on the horizon?

Norstella CEO, Mike Gallup, weighs in on the most disruptive / transformational technology on the horizon in a recent pharma’s almanac piece. “As regulators and payers look for new information to guide their decision-making, real-world data and evidence are poised to play a transformative role in not only getting drugs to market quickly, but also ensuring that patients can access them.” Read more
Press Releases | Dec. 09, 2022

Exclusive AIS Health data outlines 2021 compensation for health insurer CEOs

Washington, DC, Dec. 9, 2022 — In AIS Health’s annual roundup of health insurer executive compensation data, four newly public startup insurers stand out. But the stock awards that are largely driving their eye-popping total compensation figures — such as Clover Health Investments Corp. CEO Vivek Garipalli’s $390 million or Bright Health Group, Inc. CEO Mike Mikan’s $181 million — are based in part on the firms’ initial public offering (IPO) stock valuations, which were many times higher than what their shares are now worth. Read more
In the News | Nov. 14, 2022

Industry leaders offer reflections on 2022 and predictions for 2023

The COVID-19 pandemic has continued to evolve, forcing companies to adapt to a constantly changing landscape filled with fluid consumer expectations. Meanwhile, several other key healthcare-related trends have bubbled to the surface over that period. Read more
In the News | Nov. 14, 2022

What can we expect in pharma in 2023?

Drug pricing, CMS getting negotiating power for drug purchasing, vaccines, clinical trials, artificial intelligence, and Pharmacists becoming care givers. These are the highlights of 2022, what do the experts say we will see in 2023? We rounded up some experts and asked them just that. And join us for the next few weeks as we look at what we might see in 2023. Read more
In the News | Nov. 14, 2022

The 2023 PharmaVoice crystal ball: peering into the future of life sciences

For the 2023 PharmaVoice Year in Preview, we zeroed in on six key trends: clinical trial diversity, disruptive tech, innovation, talent management, patient engagement and leading through uncertain times. Here, we’ve asked industry execs to look into their crystal balls and tell us about anything they see coming. Read more
Press Releases | Nov. 01, 2022

Citeline and Norstella complete merger to form a $5 billion global pharmaceutical technology company

Nov. 1, 2022 – Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial intelligence space. At deal close, the $5 billion global company is now one of the world’s largest pharma intelligence solutions providers on the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now Citeline. Read more
Press Releases | Jun. 28, 2022

Citeline and Norstella unite to offer life sciences clients a full suite of commercial and clinical solutions

June 28, 2022 – Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies. Read more
Press Releases | Jun. 23, 2022

MMIT announces winners of the Q1 2022 Patient Access Awards

June 23, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has launched the inaugural Patient Access Awards to honor pharmaceutical manufacturers committed to improving patient access to life-saving therapies. Read more
In the News | Jun. 22, 2022

Merger creates $5 billion pharma technology company

Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market. Read more
In the News | Jun. 22, 2022

Norstella, Citeline merge to create $5bn pharma tech firm

Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category. Read more
In the News | Jun. 22, 2022

Norstella completes acquisition of Citeline to form $5B pharma intelligence group

Although financial terms weren’t disclosed, Norstella estimates that it is now a $5 billion player in the market, the company said in a Nov. 1 press release. The acquisition was first announced in June. Read more
In the News | Jun. 22, 2022

Norstella completes merger with Citeline to form $5B pharma tech company

The combined company has more than 1,500 employees worldwide, including about 200 in the Philadelphia region. Read more
In the News | Jun. 22, 2022

Citeline, Norstella complete $5B merger

Citeline and Norstella announced the completion of their $5 billion merger Tuesday morning. The deal, first announced in late June, creates one of the world’s largest pharmaceutical intelligence solutions providers. The combined company has $5 billion and 1,600 employees. Citeline will join four other brands, Evaluate, MMIT, Panalgo and The Dedham Group, as part of Norstella. Read more
Press Releases | May. 09, 2022

MMIT announces the winners of the seventh-annual specialty pharmacy Patient Choice Awards

May 9, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has announced the winners of the seventh-annual Specialty Pharmacy Patient Choice Awards.  Each year, MMIT hosts the Patient Choice Awards to honor specialty pharmacies that provide best-in-class customer satisfaction and overall patient care within four categories: Payer/PBM, Hospital and Health System, Independent and Retail. Read more
Press Releases | May. 03, 2022

Four prominent pharmaceutical solutions providers launch Norstella to drive innovation and get patients access to life-saving therapies faster

May 3, 2022 – Creating a hub for rapid innovation, four prominent pharmaceutical solutions providers—Evaluate, MMIT, Panalgo and The Dedham Group—are thrilled to announce the launch of Norstella. Read more
Press Releases | Feb. 17, 2022

MMIT announces game-changing solution for life sciences companies

Feb. 17, 2022, Yardley, PA – Following the acquisition of healthcare analytics company Panalgo in September 2021, Managed Markets Insight & Technology (MMIT) has announced the launch of Patient Access Analytics Read more
Press Releases | Sep. 28, 2021

MMIT/Evaluate acquire Panalgo

MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making The move will result in a disruptive, market-leading analytics platform that provides on-demand insights across dozens of normalized real-world evidence and market access data sets that support decision-making from pipeline to prescription September 28, 2021, Yardley, PA — Managed Markets Insight & Technology (MMIT) and […] Read more
Press Releases | Aug. 20, 2021

MMIT and Evaluate

MMIT and Evaluate Join Forces to Offer an End-to-End View of the Pharmaceutical Market Landscape By combining their technology, data and expertise, MMIT and Evaluate will become a $1.6 billion global pharma commercial intelligence provider August 20, 2021, Yardley, PA — Managed Markets Insight & Technology (MMIT), LLC, the trusted go-to-market partner solely focused on solving the “what […] Read more
Press Releases | Apr. 27, 2021

MMIT & The Dedham Group unite to smooth access to therapy

The combined data, technologies and expertise of both organizations will positively impact patient access to life saving treatments April 27, 2021, Yardley, PA – Managed Markets Insight & Technology, LLC. (MMIT), the trusted go-to-market partner solely focused on solving the “what and why” of market access—so that patients don’t face delays when trying to access lifesaving […] Read more
See more news

Insights

Article | Nov. 29, 2023

Worries and hopes for health care delivery in 2024

Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024. From less tolerance for failure as pressure mounts on pipelines to ongoing consequences of regulatory changes, such as the introduction of US Inflation Reduction Act, life sciences companies will face a number […] Read more
Article | Oct. 26, 2023

3 key challenges discussed at Cell & Gene Meeting on the Mesa

At the 2023 Cell & Gene Meeting on the Mesa earlier this month, senior executives and top decision-makers discussed commercialization challenges facing the cell and gene therapy sector. This year’s conference called out some of the biggest issues that the industry is facing. Leaders discussed challenges ranging from manufacturing scalability issues to gaps in Medicare […] Read more
Article | Oct. 25, 2023

6 step guide: Successfully navigating complexities of drug development

Not only is developing a new drug expensive, but an extraordinarily lengthy and complex process. In fact, some estimate that drug development can cost upwards of $2.8 billion and take 10-15 years. From the initial stages of drug discovery, clinical trials and regulatory approvals, to pre-and post-launch strategizing and commercialization, pharmaceutical companies face numerous obstacles […] Read more
REPORT | Jun. 27, 2023

How real-world evidence is impacting regulatory decision-making: A collection of 10 recent regulatory decisions based on RWE

Volume 3 Discover the power of real-world evidence (RWE) in shaping regulatory decisions through “How RWE is Impacting Regulatory Decision-Making.” Volume 3 of Panalgo’s popular use cases series reveals 10 recent instances where life sciences companies have not only invested in RWE but have successfully utilized it in their submissions to the FDA and other […] Read more
See more insights

Events

Conference | November 2023

Nordic Life Science Days

This will be a unique opportunity to partner and network with the best of Nordic and International leaders in life sciences and celebrate together our 10th anniversary.
Learn more
Conference | November 2023

Clinical Trials Europe

Your opportunity to meet with the clinical professionals changing the way we conduct trials both now and in the Future. Regulations, decentralized trials, talent resourcing, patient centricity & recruitment plus more!
Learn more

Work with us

Join our mission

We're looking for agile, growth-oriented team players who are passionate about client success and helping patients get access to the therapies they need.

Work with us

Get in Touch

Let's connect

Have questions about Norstella or its brands? Or do you want to know more about how to solve your market access challenges?

We want to hear from you